Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

doi:10.12998/wjcc.v12.i27.6057

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1581)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

HTML

674

Figures (1-2)

124

Tables (1-4)

119

Sum=945

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

192

Download

241

Sum=433

Publishing Process of This Article

Item

Count

Browse

Download

125

Sum=169

Sep 26, 2024 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. Sep 26, 2024; 12(27): 6057-6069
Published online Sep 26, 2024. doi: 10.12998/wjcc.v12.i27.6057

Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Chao-Yu Chen, Tzu-Hao Huang, Li-Wen Lee, Jrhau Lung, Yu-Che Ou, Chien-Hui Hung, Huei-Chieh Chuang, Min-Chi Chen, Ting-Yao Wang

Chao-Yu Chen, Yu-Che Ou, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Chao-Yu Chen, Chien-Hui Hung, Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

Chao-Yu Chen, Ting-Yao Wang, Department of Early Childhood Care and Education, Shu-Zen Junior College of Medicine and Management, Kaohsiung 821, Taiwan

Tzu-Hao Huang, Division of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Li-Wen Lee, Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Li-Wen Lee, Jrhau Lung, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

Jrhau Lung, Department of Medical Research and Development, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Yu-Che Ou, Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan

Huei-Chieh Chuang, Department of Anatomic Pathology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Min-Chi Chen, Department of Public Health, Chang Gung University, Taoyuan 333, Taiwan

Ting-Yao Wang, Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

Author contributions: Chen CY and Wang TY designed the research; Chen CY, Chen MC, and Lung J conducted the research; Chen MC and Wang TY analyzed the data; Chen CY, Wang TY, and Chen MC wrote the paper; Huang TH, Lee LW, Ou YC, Hung CH, and Chuang HC provided critical revision of the manuscript; Chen CY had primary responsibility for final content; and all authors read and approved the final manuscript.

Supported by the Chang Gung Medical Foundation, No. CMRPG6L0091, No. CMRPG6L0092, and No. CMRPG6L0093.

Institutional review board statement: The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (Approval No. 202001607A3).

Informed consent statement: The Institutional Review Board of Chang Gung Memorial Hospital approves the waiver of the informed consent form.

Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose.

Data sharing statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Ting-Yao Wang, MD, Chief Physician, Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, No. 8 Sec. W. Jiapu Road, Chiayi 613, Taiwan. tywang.onco@gmail.com

Received: June 4, 2024
Revised: June 25, 2024
Accepted: July 15, 2024
Published online: September 26, 2024
Processing time: 56 Days and 11.3 Hours

Core Tip

Core Tip: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can extend survival in peritoneal carcinomatosis, but outcomes vary. This study examined factors affecting progression-free survival (PFS) after CRS/HIPEC in patients with colorectal, high-grade appendiceal, ovarian, and gastric cancers. Evaluating the results of 80 patients from 2015-2020 showed that those with a completeness of cytoreduction score of 0 (CC-0) or surgery duration ≤ 6 h had better PFS. Achieving CC-0 was the key predictor of favorable PFS and longer overall survival. The study highlights the importance of patient selection for optimal CRS/HIPEC outcomes.